Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

Hikma Farmaceutica, lda

NIF 502266791
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €2,271,266 71 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €2,271,266 71 contracts
A2 · Late Publication €8,030,386,519 4,963 contracts
Contract published to BASE more than 10 days after the signing date
LOW €8,030,386,519 4,963 contracts
A5 · Threshold Splitting €7,853,423 131 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €7,853,423 131 contracts
A6 · Low Competition €152,893 4 contracts
Only one bidder participated in a competitive procedure
MEDIUM €152,893 4 contracts
A9 · Price Overrun €9,587 6 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €9,587 6 contracts
A9 · Abnormal Price Reduction €9,951,979,601 3,363 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €9,951,979,601 3,363 contracts
C3 · Missing Mandatory Fields €2,754,052 118 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €2,754,052 118 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

936
€1,010,757,304
165
€469,249,710
45
€451,308,109
414
€414,296,075
218
€397,490,300
554
€380,278,495
203
€334,224,015
69
€326,706,780
155
€313,693,316
46
€306,698,622
124
€303,734,642
177
€289,977,073
67
€285,209,788
83
€258,360,298
56
€252,308,550
272
€250,998,674
44
€248,698,274
75
€247,457,243
99
€218,259,612
32
€216,735,749
Page 1 of 4 · 70 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 6 contracts

Medicamentos
PT · 7dabb4e73c923b0654ac · Ajuste Direto Regime G...
A9 · Price Overrun
€163 2025-06-26
Medicamentos
PT · 362e99701a2379085338 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Price Overrun
€398 2025-06-12
Medicamentos
PT · 220b401043f7d0994ad4 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Price Overrun
€1,523 2025-06-03
Medicamentos
PT · adbb8715b0913ad34fda · Ajuste Direto Regime G...
A2 · Late Publication A9 · Price Overrun
€3,925 2025-06-03
FI0042/2017 - MED. ANESTESICOS E RELAXANTES MUSCULARES
PT · 4207366 · Ao abrigo de acordo-qu...
A9 · Price Overrun A2 · Late Publication
€3,276 2017-02-15
MED. ANTI-INFECCIOSOS
PT · dc09fa201cc9c54f6888 · Ajuste direto
A2 · Late Publication A9 · Price Overrun
€300 2014-12-05
Overview
Total Value Won
€10,008,211,646
Contracts Won
6,767
Score 243055 · CRITICAL RISK
NIF
502266791
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.F. [P-7c29]
    Presidente
    since 2019-12-10
  • C.C. [P-6569]
    Vogal
    since 2019-12-10
  • H.O. [P-25e8]
    Vogal
    since 2015-09-14
  • H.O. [P-25e8]
    Vogal
    since 2019-12-10
  • H.O. [P-25e8]
    vogal
    since 2023-03-21
  • I.T. [P-438f]
    Vogal
    since 2019-12-10
  • M.A. [P-3c0f]
    Administrador
    since 2010-11-30
  • M.A. [P-3c0f]
    administrador
    since 2014-11-18
  • M.A. [P-3c0f]
    Vogal
    since 2019-12-10
  • M.S. [P-dd4b]
    Presidente
    since 2010-11-30
  • M.S. [P-dd4b]
    presidente
    since 2014-11-18
  • M.S. [P-dd4b]
    presidente
    since 2019-12-10
  • M.S. [P-dd4b]
    presidente
    since 2023-03-21
  • M.A. [P-bb0d]
    Administrador
    since 2010-11-30
  • M.A. [P-bb0d]
    adminstrador
    since 2014-11-18
  • P.A. [P-5b27]
    Vogal
    since 2017-12-22
  • S.S. [P-c685]
    Administrador
    since 2010-11-30
  • S.S. [P-c685]
    administrador
    since 2014-11-18
  • S.S. [P-c685]
    Vogal
    since 2019-12-10
  • S.S. [P-c685]
    Vogal
    since 2023-03-21
  • S.T. [P-acd0]
    Administrador
    since 2010-11-30
  • S.T. [P-acd0]
    administrador
    since 2014-11-18
  • S.T. [P-acd0]
    Vogal
    since 2015-09-14
  • C.J. [P-e2b7]
    Fiscal Único
    since 2017-04-24
  • D.A. [P-c2b1]
    Fiscal Único
    since 2010-11-30
  • J.L. [P-36f4]
    Fiscal Único
    since 2010-11-30
  • P.A. [P-4562]
    Fiscal Único
    since 2017-04-24
  • J.C. [P-4efc]
    Vogal
    2017-12-22 → 2018-12-04
  • J.E. [P-2f62]
    Administrador
    2021-10-20 → 2023-03-12
  • M.A. [P-bb0d]
    Vogal
    2019-12-10 → 2021-10-20
  • P.A. [P-5b27]
    Vogal
    2019-12-10 → 2022-08-02
  • R.A. [P-283b]
    Administrador
    2025-08-12 → 2026-01-14
  • C.L. [P-db3e]
    Fiscal Único
    2014-11-18 → 2017-04-24
  • D.A. [P-c2b1]
    Fiscal Único
    2014-11-18 → 2017-04-24
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned